Ryvu Therapeutics S.A. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was PLN 38.95 million compared to PLN 11.19 million a year ago. Revenue was PLN 68.44 million compared to PLN 35.41 million a year ago.

Net loss was PLN 83.78 million compared to PLN 79.08 million a year ago. Basic loss per share from continuing operations was PLN 4.56 compared to PLN 4.31 a year ago. Diluted loss per share from continuing operations was PLN 4.56 compared to PLN 4.31 a year ago.